General Applications

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately-held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, implantable extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance.

Envisia and Liquidia are independent companies with distinct areas of focus, dedicated teams and independent funding. Initially, Neal Fowler and his executive team will lead both Envisia and Liquidia. 

Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.

All your information will be kept confidential according to EEO guidelines.